Superficial Venous-Associated Inflammation from Direct IV Administration of RRx-001 in Rats
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Medical Sciences"
DOI: 10.7150/ijms.76615
Abstract: RRx-001 is a small molecule NLRP3 inflammasome inhibitor with anti-CD47 and antiangiogenic/vascular normalization properties in a Phase 3 clinical trial that has been designated as a drug-device combination by the FDA. In the Phase 1… read more here.
Keywords: superficial venous; administration; venous associated; associated inflammation ... See more keywords